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The identification of a soluble factor that protects cells 
from viral infection was first made by Isaacs and Linden‑
mann in 1957 (Isaacs and Lindenmann, 1957; Isaacs et al., 
1957). We now know that multiple species of type I IFN 
exist, with this heterogeneity arising from the presence of 
13 functional α genes and one β gene situated syntenically 
on human chromosome 9p (Manry et al., 2011). However, 
despite almost 60 years of active research in this field, the 
direct measurement of type I IFN protein in biological 
samples has remained elusive. Type I IFN mRNA is usu‑
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ally present at only trace levels in PBMCs from healthy 
individuals, and current ELI SAs have proven either insen‑
sitive or unreliable, leading to the development of proxy 
assays based on type I IFN signaling (Hua et al., 2006; 
Niewold et al., 2009; Seo et al., 2009; Li et al., 2010; Berger 
Rentsch and Zimmer, 2011). Such presumed low levels of 
circulating IFN protein likely reflect the high biological 
potency of these cytokines, with most cell types express‑
ing a type I IFN receptor.
Balanced against its beneficial role in antiviral pro‑
tection, nonphysiological exposure to IFN can have major 
detrimental effects (Hunt et al., 2014). This point is well 
illustrated by the complex disorders systemic lupus erythe‑
matosus (SLE) and dermatomyositis (DM) and the recently 
defined group of monogenic autoinflammatory diseases re‑
ferred to as the type I interferonopathies, where persistent 
type I IFN‑induced signaling is considered causal to pa‑
thology (Hooks et al., 1979; Greenberg et al., 2005; Crow, 
2011; Rodero and Crow, 2016). However, the mechanis‑
tic dissection of these pathologies has been hampered by 
the inability to directly quantify the disease‑causing pro‑
tein. This also represents a major unmet clinical need be‑
cause such a test could improve diagnosis and therapeutic 
monitoring in the context of infection, autoimmunity and 
type I interferonopathies.
To overcome this limitation, we took advantage of 
a new digital ELI SA technology based on counting in‑
dividual enzyme‑labeled immunocomplexes of proteins 
captured on paramagnetic beads in single‑molecule arrays 
(Simoa; Rissin et al., 2010; Wilson et al., 2016). Combin‑
ing this technology with unique high‑affinity antibodies 
isolated from APS1/APE CED mutation patients (Meyer 
et al., 2016) enabled the direct quantification of IFNα at 
attomolar (femtograms per milliliter) concentrations. With 
this 5,000‑fold increase in sensitivity over commercial 
ELI SAs, we could directly measure elevated IFNα pro‑
tein in patients with adult and juvenile‑onset SLE (JSLE) 
and juvenile‑onset dermatomyositis (JDM), a group of 
molecularly distinct type I interferonopathies and acute 
viral meningitis. IFN protein quantification by Simoa was 
highly correlated with IFN antiviral activity and interfer‑
on‑stimulated gene (ISG) expression measured in serum 
and in the cerebrospinal fluid (CSF) of all patients exam‑
ined. Finally, differences within disease groups were ob‑
served based on serum IFNα protein levels and between 
diseases as indicated by the results of our studies on the 
cellular source of IFNα protein.
These data show that the measurement of IFNα protein 
by digital ELI SA is a sensitive, reliable, and biologically rele‑
vant method that can be used for the diagnosis, stratification, 
and therapeutic monitoring of pathological states associated 
with an up‑regulation of type I IFN signaling. The ability to 
directly measure IFNα protein levels will facilitate a better 
understanding of the nature, regulation, and impact of the 
human IFN‑induced response.
rESuLtS
direct quantification of IFnα in plasma, serum, and cSF
To confirm the specificity of our Simoa assay for human 
IFNα, and non–cross‑reactivity for other IFNs, we tested 
these antibodies against IFNβ, IFNλ1, IFNλ2, IFNω, and 
IFNγ recombinant proteins (Fig.  1  A) and 16 subtypes of 
IFNα that included three commercially available IFNα2 
types; namely, IFNα2a, IFNα2b, and IFNα2c (Fig. 1 B). Our 
assay did not cross‑react with other IFNs and was able to 
detect all IFNα subtypes, although a lower affinity for IFNα2 
was observed (Fig. S1 A). Because its standard curve was 
representative of all other subtypes, IFNα17 (IFNαI) was 
chosen as our reference protein. To further define the speci‑
ficity of these reagents, we performed a competition assay in 
plasma samples from five SLE patients. Addition of anti‑IFNα 
antibody–depleted the signal, showing a specific detection of 
IFNα in the tested samples (Fig. 1 C). Reproducibility was 
assessed across three assays (Fig. 1 D), and the mean of three 
blanks +3 SD was used to calculate the limit of detection 
(LOD). The mean of all LODs was calculated at 0.23 fg/ml, 
and this value was multiplied by our standard dilution factor 
(×3) to give a measure of 0.69 fg/ml, which was used to re‑
place all undetectable values for presentation purposes. Assay 
reproducibility was also assessed by the measurement of IFNα 
protein in 22 plasma samples from 8 SLE, 8 JDM, 3 Aicardi–
Goutières syndrome (AGS), and 3 TMEM173‑mutated/ 
STI NG patients, using two independently prepared lots of 
beads, performed by different users at different times (Rs = 
0.978, P = 0.0001; Fig. 1 E). Analyzing 10 matched plasma and 
serum samples from AGS patients revealed a strong correla‑
tion (Rs = 0.958, P = 0.0001; Fig. 1 F), indicating a negligible 
influence of blood processing on IFNα concentration and the 
ability to use either sample for retrospective patient screening.
To determine the potential diagnostic capability of 
our assay, we examined collections of plasma and serum 
established during the study of Mendelian type I interfer‑
onopathies (27 patients in total), attributable to mutations 
in TREX1 (n = 4), RNA SEH2A (n = 1), RNA SEH2B 
(n = 6), RNA SEH2C (n = 2), SAM HD1 (n = 2), ADAR1 
(n = 2), IFIH1 (n = 3), and TMEM173 gain of function 
(n = 7; STI NG). We also analyzed samples from patients with 
JDM (n = 43) and SLE (n = 72; both juvenile and adult 
forms; n = 6 and 66, respectively). We compared these data 
with samples from 20 healthy control subjects and patients 
with specific autosomal‑dominant mutations in the 3′ end 
of TREX1 causing retinal vasculopathy and cerebral leuko‑
dystrophy (RVCL) which has not previously been associated 
with increased type I IFN signaling (n = 30). Clinical char‑
acteristics of these patient and control groups are described 
in Tables S1, S2, S3, S4, S5, and S6. A one‑way ANO VA 
test (Kruskal–Wallis) and Dunn’s post test controlling for 
multiple comparison testing revealed significantly elevated 
IFNα in the monogenic interferonopathy (P < 0.0001), JDM 
(P < 0.0001), and SLE (P < 0.0001) groups as compared 
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associations with these clinical phenotypes (Fig.  2  A). In 
contrast, RVCL patients showed no difference in comparison 
to healthy controls (median 1.6 fg/ml; interquartile range 
[IQR] 0.95–4.6 fg/ml; Fig. 2 A). Multiple group testing also 
demonstrated that patients with a molecularly determined 
interferonopathy had significantly higher IFNα (median 310 
fg/ml; IQR 71–2,223 fg/ml) in comparison to SLE (median 
20 fg/ml; IQR 0.69–234 fg/ml; P < 0.001), but not to JDM 
(median 56 fg/ml; IQR 14–120 fg/ml) patients (Fig. 2 A).
As expected, given the fundamental role of IFN in an‑
tiviral protection, testing of CSF from patients with central 
nervous system (CNS) infection (acute meningitis, n = 9; 
acute encephalitis, n = 9; acute meningoencephalitis, n = 1) 
revealed very high levels of IFNα protein (Fig. 2 B: median 
4,174.2 fg/ml; IQR 2,437.4–11,173 fg/ml). In contrast, all 
but one patient with RVCL (n = 12) demonstrated an IFNα 
protein level of less than 10 fg/ml (P < 0.001, Mann–Whitney 
test as compared with infection samples).
IFnα concentration correlates with 
functional antiviral activity
To investigate the functional relevance of such low protein 
levels, we compared IFNα protein measurements with IFN 
activity as assessed by a cytopathic protection assay (Lebon 
et al., 1979, 1988; Palmer et al., 2007). Specifically, IFN ac‑
tivity is determined by dilution of patient material incubated 
with Madin–Darby bovine kidney cells. Cells are challenged 
the next day with vesicular stomatitis virus and examined 
18 h postinfection to measure the viral cytopathic effect. Cell 
protection against infection reveals the biological activity 
of type I IFN, which is compared with serial dilutions of 
an IFN standard. Comparing these assays on serum samples 
(Fig. 3 A: 25 JDM, 2 JSLE, and 11 monogenic interferonop‑
athy patients, either AGS or STI NG; Table S7) demonstrated 
a positive correlation (Rs = 0.83; P < 0.0001). Considering 
the potential contribution of type I IFNs to CNS disorders, 
we performed a similar comparison on the CSF samples pre‑
Figure 1. Specificity, sensitivity, and reproducibility of the Simoa IFnα assay. (A) Simoa IFNα assay reactivity with IFNα17, IFNβ, IFNλ1, IFNλ2, IFNω, 
and IFNγ recombinant proteins. Lowest concentration is the blank. (B) Simoa IFNα assay cross-reactivity with IFNα1, IFNα1 (Val114), IFNα2a, IFNα2b, IFNα2c, 
IFNα4a, IFNα4b, IFNα5, IFNα6, IFNα7, IFNα8, IFNα10, IFNα14, IFNα16, IFNα17, and IFNα21. (C) Simoa IFNα competition assay; measurement of IFNα in five 
SLE patient plasma samples after preincubation with the human anti-IFNα capture antibody for 30 min before analysis. (D) Reproducibility testing for each 
concentration, acquired as duplicates across three independent runs. Dashed line represents the LOD, defined by mean blank average enzyme per bead (AEB) 
+ 3 SD of all runs. (E) 22 plasma samples (8 SLE, 8 JDM, 3 AGS, and 3 STI NG) were analyzed with two independently prepared lots of beads by different users 
and at different times. Spearman correlation is reported. (F) Correlation of IFNα protein measured by Simoa in paired plasma and serum samples from 10 
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sented in Fig.  2  B. This analysis revealed an even stronger 
positive correlation between IFN activity and concentration 
(Rs = 0.924, P < 0.001). To note, statistical analysis was per‑
formed on samples with either detectable IFN activity (≥2 
IU/ml) or IFN protein (>0.69 fg/ml; Fig. 3 B). Interestingly, 
10 serum samples and 1 CSF sample had IFNα concentra‑
tion >10 fg/ml with no detectable antiviral activity, reflecting 
either the increased sensitivity of the Simoa assay or the pres‑
ence of posttranslational (or other) modifications that may 
alter functional potency.
comparison of IFnα concentration with ISG expression
We have previously described a screening tool for the identifi‑
cation of monogenic type I interferonopathies based on quan‑
titative PCR assessment of six ISGs expressed by leukocytes 
(Rice et al., 2013, 2017). In this test, the median fold change 
of the ISGs when compared with the median of healthy con‑
trols is used to create an IFN score. Scores two SDs above 
the median of 29 controls are designated as positive (score 
of >2.466). We compared Simoa IFNα measurements with 
the ISG score of samples from 31 SLE (Fig. 3 C), 24 JDM 
(Fig. 3 D), and 29 monogenic interferonopathy (Fig. 3 E and 
Table S8) patients, excluding patients who had negative re‑
sults for both tests (10 SLE and 1 JDM patients). This analysis 
revealed a positive correlation between the two parameters in 
all three groups (SLE, Rs = 0.787, P < 0.0001 [n = 31]; JDM, 
Rs = 0.665, P = 0.0004 [n = 24]; interferonopathies, Rs = 
0.635, P = 0.0002 [n = 29]). As type I interferonopathies are 
associated with a broad range of phenotypes at least partially 
determined by genotype, we grouped patients according to 
identified mutations (color coded in Fig. 3 E), but this did 
not obviously affect the correlation. To note, two outliers in 
the SLE cohort showed either high ISG expression with no 
detectable IFNα or vice versa, although the explanation for 
such phenotypes is not clear.
Association of disease phenotypes with 
serum IFnα in lupus patients
To examine whether serum IFNα concentrations were rele‑
vant to disease status, we focused on the SLE cohort. SLE is 
a complex and heterogeneous disease, and as such, a number 
of different biomarkers are used to monitor disease severity 
and progression. For this analysis, we divided the SLE pa‑
tients into three groups based on serum IFNα concentrations: 
<10 fg/ml (n = 25), 10–300 fg/ml (n = 14), and >300 fg/ml 
(n = 8; Fig. 4). In these subgroups, we examined (a) SLE dis‑
ease activity index (SLE DAI), (b) erythrocyte sedimentation 
rate (ESR), (c) CH50 activity, (d) number of autoantibodies, 
and (e) profile of autoantibodies directed against ribonuc‑
leoproteins. An ANO VA with Dunn’s post testing revealed 
significantly higher α‑RNP antibodies (P < 0.0001), ESR 
(P < 0.01), and SLE DAI (P < 0.01) and lower CH50 activity 
(P < 0.001) in patients who had the highest levels of serum 
IFNα. In contrast, anti–double‑stranded DNA antibodies and 
C‑reactive protein (CRP) activity showed no differences be‑
tween the subgroups (Table S9).
Identification of cellular sources of IFnα
To explore cellular mechanisms driving disease pathogen‑
esis, we next considered the source of IFNα detected in 
patients. We sampled blood from three STI NG, four AGS, 
three JDM, three SLE patients, and four healthy donors, 
and we isolated CD4+ and CD8+ T cells, B cells, NK cells, 
CD14+ monocytes, and plasmacytoid DCs (pDCs). A rep‑
Figure 2. Quantification of plasma, serum, and cSF IFnα in patient cohorts. (A) Plasma from healthy controls (n = 20) and patients with RVCL 
(n = 30), SLE (n = 72), JDM (n = 43), and molecularly defined interferonopathies (n = 27) were assayed by Simoa for IFNα protein. Values were assessed 
by one-way ANO VA test (Kruskal–Wallis) and Dunn’s multiple comparison testing between groups. (B) CSF samples from acute meningitis (n = 9), acute 
encephalitis (n = 9), acute meningoencephalitis (n = 1), and RVCL (n = 12) were assayed by Simoa for IFNα protein. Values were assessed by Mann–Whitney 
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resentative flow cytometry panel with the gating strategy is 
shown in Fig. S2. The percentage of each cell population 
is presented in Table S10, the purity of sorted cell num‑
bers are detailed in the materials and Table S11, and clini‑
cal characteristics of these patients are detailed in Table S12. 
Cell subsets were isolated, lysed, and assessed with our IFNα 
Simoa assay. To calculate the level of protein present per cell, 
we divided the concentration of IFNα by the number of 
cells sorted and normalized for the volume in which the 
cells were lysed. This revealed a striking presence of IFNα in 
the monocytes and pDCs of STI NG patients, with a mean 
of 1.03 attograms/cell in pDCs and 1.53 attograms/cell in 
monocytes (Fig.  5). Notably, no other cell types from the 
STI NG patients, or any cell type analyzed from the other 
patient groups tested, demonstrated levels of IFNα above 
those in healthy controls. This was despite the high levels of 
IFNα observed in plasma, suggesting a noncirculating cel‑
lular source of IFNα protein in these diseases. This discrep‑
ancy in the cellular source of IFNα between monogenic 
interferonopathy patients highlights a potential cell type–
specific mechanism dependent on genes involved in nucleic 
acid metabolism or sensing.
dIScuSSIon
In conclusion, we report here that the ultrasensitive detection 
of IFNα protein in human material can provide novel insights 
into disease‑causing pathways. The transformational increase 
in sensitivity over conventional methods that we present 
derives from the combination of the Simoa digital ELI SA 
and the extremely high affinity of the human mAbs iso‑
lated from APS1/APE CED mutation patients (Meyer et al., 
2016). In this way, we were able to identify circulating pDCs 
and monocytes as a constitutive source of IFNα protein in 
STI NG mutation patients. Although pDCs are recognized 
as the major type I IFN‑producing leukocyte (Siegal et al., 
1999), they were not apparently implicated in AGS, JDM, or 
SLE patients in our study, possibly suggesting tissue seques‑
tration of these cell types or an additional cellular source of 
IFNα in these conditions. However, the number of pDCs iso‑
lated was low, in particular from SLE patients, so that these 
Figure 3. comparison of IFnα concentration with antiviral activity and ISG expression. (A) Correlation of Simoa IFNα protein measurement with 
IFN activity measured by a cytopathic assay for interferonopathy (n = 10), JDM (n = 26), and JSLE (n = 2) patients. (B) Correlation of Simoa IFNα protein 
measurement with IFN activity measured by a cytopathic assay for CSF samples from acute viral meningitis (n = 9), acute viral encephalitis (n = 9), acute 
viral meningoencephalitis (n = 1), AGS (n = 1), and RVCL (n = 12). (C–E) Correlation of Simoa IFNα concentration with the ISG score in SLE (C; n = 21), JDM 
(D; n = 23), and molecularly defined interferonopathy patients (E; n = 29). Spearman correlations were calculated for each patient group, excluding samples 
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results will require additional confirmatory experiments. The 
current lack of a test to measure type I IFN protein in rou‑
tine medical practice represents a major unmet clinical need. 
The potential of direct measurement of IFN protein per se 
as a disease biomarker is obvious and will be immediately 
relevant in SLE, where anti‑IFNα and anti‑IFN AR therapies 
are currently being tested (Lauwerys et al., 2014). Indeed, our 
data identified lupus patients with low or high IFNα con‑
centrations, which differentiated patients based on a num‑
ber of disease‑relevant phenotypes, and as such could be used 
for future patient stratification, as well as for on‑treatment 
monitoring. Such changes might also be of clinical relevance 
in other situations, as evidenced by the risk of developing 
IFN‑driven pathology in the context of TNF blockade 
(Conrad et al., 2015). Furthermore, our ability to detect and 
quantify IFNα in different sample types from virally infected 
patients suggests possible clinical utility in the assessment of 
disease severity. For these reasons, we consider that digital 
ELI SA technology can play a central role in future manage‑
ment of many different disease states.
MAtErIALS And MEtHodS
Subjects and samples
Historical serum, plasma, and CSF samples were collected 
from patients demonstrating the presence of biallelic muta‑
tions in TREX1, RNA SEH2A, RNA SEH2B, RNA SEH2C, 
SAM HD1, and ADAR1, as well as recognized dominant dis‑
ease‑causing mutations in TREX1, and from patients with 
dominant mutations in IFIH1 and TMEM173 (STI NG). 
Samples from patients with SLE and DM demonstrated clin‑
ical criteria conforming to American College of Rheuma‑
tology and Bohan and Peter criteria, respectively. Historical 
samples for IFN activity studies were collected across the pe‑
riod 1985–2015. All samples were collected with informed 
consent. The study was approved by the Leeds (East) Research 
Ethics Committee (reference number 10/H1307/132), by the 
Comité de Protection des Personnes (ID‑RCB/EUD RACT: 
2014‑A01017‑40), and South‑East Scotland Research Ethics 
Committee (0114/SS/0003). In Fig. 2, only the first sample 
collected from each individual patient was plotted (Tables S1, 
S2, S3, S4, and S5). For the correlation analysis in Fig. 3, se‑
rial samples from the same patient were used (Tables S7 and 
S8). SLE disease activity was assessed by an experienced rheu‑
matology nurse specializing in SLE, who interviewed each 
patient and had access to all medical data and blood results 
using the SLE DAI 2000. SLE patients also had blood tests at 
the relevant clinic visits including CH50, C3, C4, autoanti‑
body testing, CRP, and erythrocyte sedimentation rate (ESR), 
which were performed in a fully accredited NHS laboratory 
(Wiseman et al., 2016).
Simoa assay development
The Simoa IFNα assay was developed using a Quanterix 
Homebrew Simoa assay according to the manufacturer’s 
instructions and using two autoantibodies specific for 
IFNα isolated and cloned from 2 APS1/APE CED pa‑
tients recently described (Meyer et al., 2016 and patent 
application WO2013/098419). The 8H1 antibody clone 
was used as a capture antibody after coating on paramag‑
netic beads (0.3mg/ml), and the 12H5 was biotinylated 
(biotin/antibody ratio = 30/1) and used as the detector. 
EC50 binding of the mAbs was determined by ELI SA as 
Figure 4. disease associations of serum IFnα in SLE patients. (A–D) 
Higher serum IFNα levels associate with higher SLE DAI (P < 0.001; A), ESR 
(P < 0.01; B), lower CH50 activity (P < 0.001; C), and number of specific auto-
antibodies against ribonucleoproteins (anti-Ro, La, Sm, RNP; P < 0.0001; D). 
IFNα <10 fg/ml: n = 25; IFNα = 10–300 fg/ml: n = 14; IFNα >300 fg/ml: 
n = 8; one-way ANO VA (Kruskal–Wallis) p-values are reported. (E) Pro-
file of autoantibodies directed against ribonucleoproteins in patients with 
low, intermediate, and high IFN levels. Green, <25 U/ml; yellow, 25–50 U/ml; 
orange, 50–100 U/ml; red, >100 U/ml. A positive result is >25 U/ml. The 
total number of autoantibodies against ribonucleoproteins (anti-Ro, La, Sm, 
RNP) is significantly increased in patients with the highest levels of serum 
IFNα (two-way ANO VA, P < 0.0001). *, P < 0.05; **, P < 0.01; ***, P < 0.001; 
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previously described (Meyer et al., 2016) and observed 
to be 4.02 ng/ml and 4.4 ng/ml for 8H1 and 12H5, re‑
spectively, for IFNα5. The IC50 was determined using an 
ISRE‑Luciferase reporter assay (described in Meyer et al., 
2016), with results presented for both antibodies against 
all IFNα subtypes in Fig. S1 A. For the Simoa assay, re‑
combinant IFNα17/αI (PBL Assay Science) was used as 
a standard curve after cross‑reactivity testing (Fig.  1  B). 
The LOD was calculated by the mean value of all blank 
runs + 3 SDs and was 0.23 fg/ml. Nonspecificity was 
demonstrated against IFNβ, IFNλ1, IFNλ2, IFNω, and 
IFNγ (PeproTech and PBL Assay Science), and cross‑re‑
activity was tested against IFNα1, IFNα1(Val114), IFNα2b, 
IFNα4a, IFNα4b, IFNα5, IFNα6, IFNα7, IFNα8, IFNα10, 
IFNα14, IFNα16, IFNα17, and IFNα21 (all PBL Assay 
Science), IFNα2a (PeproTech), and IFNα2c (eBioscience). 
Additional specificity of the assay was demonstrated in a 
competition assay where SLE patient plasma samples (n 
= 5) were 1/3 diluted with PBS and preincubated with 
50 µg/ml of the IFNα capture antibody for 30 min at 
room temperature before Simoa analysis. For Simoa mea‑
surements, biological samples were diluted from 1/3 to 
1/30 depending on the amount of material available and 
to avoid saturation. Samples with signal below the LOD 
were normalized to 0.69 fg/ml (LOD × 3, the minimal 
dilution factor) for presentation and analysis purposes.
Figure 5. Identification of circulating IFnα-producing cells in StI nG patients. IFNα protein levels presented as median attograms per cell in sorted 
CD4 and CD8 T cells, NK cells, B cells, monocytes, and pDCs from STI NG mutation (red, n = 3), JDM (blue, n = 3), AGS (green, n = 4), and SLE (purple n = 3) 
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IFn activity assay
Type I IFN activity was measured by determining the cy‑
topathic reduction (i.e., protection of Madin–Darby bo‑
vine kidney cells against cell death after infection with 
vesicular stomatitis virus) afforded by patient CSF/serum. 
A reference of human IFNα, standardized against the 
National Institutes of Health reference Ga 023–902‑530, 
was included with each titration. IFNα activity in normal 
healthy serum is <2 IU/ml.
Assessment of ISG expression in blood cells
Blood was collected into PAXgene tubes (PreAnalytix), and 
total RNA was extracted using a PAXgene (PreAnalytix) 
RNA isolation kit. RNA concentration was assessed using a 
spectrophotometer (FLUOstar Omega; Labtech). Quantitative 
reverse transcription polymerase chain reaction (qPCR) anal‑
ysis was performed using the TaqMan Universal PCR Mas‑
ter Mix (Applied Biosystems) and cDNA derived from 40ng 
total RNA. Using TaqMan probes for IFI27 (Hs01086370_
m1), IFI44L (Hs00199115_m1), IFIT1 (Hs00356631_g1), 
ISG15 (Hs00192713_m1), RSAD2 (Hs01057264_m1), and 
SIG LEC1 (Hs00988063_m1), the relative abundance of each 
target transcript was normalized to the expression level of 
HPRT1 (Hs03929096_g1) and 18S (Hs999999001_s1) and 
assessed with the Applied Biosystems StepOne Software v2.1 
and DataAssist Software v.3.01. For each of the six probes, 
individual (patient and control) data were expressed relative 
to a single calibrator (control C25). The median fold change 
of the six ISGs, when compared with the median of the com‑
bined 29 healthy controls, was used to create an IFN score for 
each patient. RQ is equal to 2−ΔCt (i.e., the normalized fold 
change relative to a control). When a patient was assayed on 
more than one occasion, the data for repeat measurements 
were combined to calculate a mean value (using DataAssist 
software v.3.01; Applied Biosystems).
cell sorting and lysis for Simoa analysis
PBMCs were isolated from blood using lymphocyte sep‑
aration medium. Just after isolation, PBMCs were labeled 
with CD3 Krome Orange, CD8 pCp‑Cy5, CD11c PE, 
CD19 PE‑Cy7, CD56 FITC, CD14 APC‑Alexa Fluor 750 
and HLA‑DR Pacific Blue. PBMC subsets were isolated 
using a BD FACS Aria II according to the gating strategy 
presented in Fig. S1. Purity of the cell sorting was verified 
for nine individual donors and was high for all populations 
(mean ± SD for CD4: 97% ± 3.2, CD8: 97.2% ± 1.4, 
B cells: 97.5% ± 2.3, natural killer cells: 97.9% ± 1.6, 
monocytes: 97.7% ± 2.6, pDCs: 96.9% ± 2.3). After sort‑
ing, cells were pelleted and lysed in 50  µl RIPA buffer 
containing 1x of Halt protease inhibitor cocktail. Details 
of cell numbers and IFNα concentration are provided in 
Table S11. Clinical characteristics of these patients are 
described in Table S12. Cell populations were not sorted 
from virally infected patients because of ethical restrictions 
on obtaining sufficient blood volumes.
Statistical analysis
GraphPad Prism was used for statistical analysis. ANO VA 
tests (Kruskal–Wallis) with Dunn’s post testing for multiple 
comparisons were used to test for differences between patient 
groups, with median and IQRs reported. Correlations be‑
tween the different assays were calculated using Spearman test.
online supplemental material
Fig. S1 shows affinity measurements of the antibodies used 
in the Simoa assay. Fig. S2 shows the gating strategy for cell 
sorting. Tables S1–S7 list clinical characteristics of the pa‑
tient cohorts. Table S8 provides information on data used 
for Fig. 3 (C–E). Table S9 provides demographic and clini‑
cal associations of raised serum IFNα levels in SLE patients. 
Table S10 shows circulating leukocyte frequencies in STI NG, 
AGS, JDM, SLE, and controls. Table S11 shows sorted cell 
numbers and IFNα concentrations. Table S12 shows clinical 
information of patients studied for cell subset IFNα content.
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